EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Xilio Therapeutics's enterprise value is $-35.68 Mil.
Xilio Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-55.26 Mil. Therefore, Xilio Therapeutics's EV-to-EBITDA for today is 0.65.
The historical rank and industry rank for Xilio Therapeutics's EV-to-EBITDA or its related term are showing as below:
XLO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.5 Med: 0.04 Max: 0.69
Current: 0.65
During the past 6 years, the highest EV-to-EBITDA of Xilio Therapeutics was 0.69. The lowest was -0.50. And the median was 0.04.
XLO's EV-to-EBITDA is ranked better than 72.78% of 496
companies
in the Biotechnology industry
Industry Median: 7.77
vs XLO: 0.65
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Xilio Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Xilio Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Xilio Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Xilio Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xilio Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xilio Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Xilio Therapeutics's EV-to-EBITDA falls into.
Xilio Therapeutics's current Enterprise Value is $-35.68 Mil.
Xilio Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-55.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Xilio Therapeutics's PE Ratio (TTM) for today is calculated as:
Xilio Therapeutics's share price for today is $0.918.
Xilio Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.840.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Xilio Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XLO has been successfully added to your 